Sickle Cell, Pain and Mediterranean Diet
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- University of Illinois at Chicago
- Study ID
- NCT06886477
- Status
- Recruiting
Conditions
- Mediterranean Diet
- Sickle Cell
- Sickle Cell Disease
- Sickle Cell Disease Without Crisis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Mediterranean Diet — OTHERMediterranean Diet foods will be provided for 4 weeks.
- Usual Diet — OTHERParticipants will consume their typical at home-diet.
Study Details
The goal of this study is to compare pain levels in individuals with Sickle Cell Disease while following the Mediterranean Diet to pain levels while following their usual diet.
Key Dates
- Start date
- May 1, 2025
- Status verified
- Apr 2026
- Primary completion
- Jun 30, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Mediterranean DietCommercially prepared foods will be provided.
- Active Comparator: Usual DietConsume their typical at-home diet.
Primary Outcome Measure
Serum and Fecal Short Chain Fatty Acids [ Time Frame: Baseline and day 27 or 28 of each diet ]
Central Contacts
- Lisa Tussing-Humphreys, PhD, MS, RD312-355-5521
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Illinois Chicago | Chicago | Illinois | 60612 |
Find similar trials in Chicago, IL
By condition
By research site
Related Studies
- Sickle Cell Clinical Research and Intervention ProgramRecruiting · St. Jude Children's Research Hospital · Peoria, Illinois
- Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell DiseasePHASE2 · Recruiting · University of Illinois at Chicago · Chicago, Illinois
- Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell DiseasePHASE2 · Recruiting · Robert Nickel · Washington D.C., District of Columbia
- A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell DiseasePHASE1 · Recruiting · EpiDestiny, Inc. · Chicago, Illinois